Olanzapine in bipolar disorder

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 7, 2004, Pages 1613-1619

  Vieta, Eduard ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Bipolar disorder; Clinical trials; Depression; Mania; Olanzapine; Prophylaxis

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CLONAZEPAM; CLOZAPINE; FLUOXETINE; HALOPERIDOL; LITHIUM; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID;

AGRANULOCYTOSIS; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BODY WEIGHT DISORDER; CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; MANIA; METABOLIC SYNDROME X; MONOTHERAPY; NEUROLOGIC DISEASE; PARKINSONISM; RELAPSE; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; WEIGHT GAIN;

BENZODIAZEPINES; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; HUMANS; MULTICENTER STUDIES; SPAIN;

EID: 3543076501     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.7.1613     Document Type: Article

References (45)

1. TOHEN M, ZHANG F, TAYLOR CC et al.: A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. J. Affect. Disord. (2001) 65(1):85-93.
2. KECK PE JR, MC ELROY SL, STRAKOWSKI SM et al.: Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder. J. Clin. Psychiatry (1996) 57:147-151.
3. ZÁRATE CA, TOHEN M: Antipsychotic drug treatment in first-episode mania: a 6 month longitudinal study. J. Clin. Psychiatry (2000) 61:33-38.
4. DUMAN RS: Synaptic plasticity and mood disorders. Mol Psychiatry (2002) 7(Suppl. 1):S29-S34.
5. MILLER DS, YATHAM LN, LAM RW: Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania. J. Clin. Psychiatry (2001) 62(12):975-980.
6. STRAKOWSKI SM, DELBELLO MP, ADLER C: Comparative efficacy and tolerability of drug treatments for bipolar disorder. CNS Drugs (2001) 15:701-718.
7. COOKSON J: Use of antipsychotic drugs and lithium in mania. Br. J. Pychiatr. Suppl. (2001) 41:144-156.
8. VIETA E, HERRAIZ M, PARRAMON G et al.: Risperidone in the treatment of mania: Efficacy and safety results from a large, multicenter, open study in Spain. J. Affect. Disord. (2002) 72:15-19.
9. AMERICAN PSYCHIATRIC ASSOCIATION: Work Group on Bipolar Disorder. Practice guideline for the treatment of patients with bipolar disorder revised. Am. J. Psychiatry (2002) 159(Suppl.):1-50.
10. YATHAM LN: The role of novel antipsychotics in bipolar disorders. J. Clin. Psychiatry (2002) 63(Suppl. 3):10-14.
11. BOTTRI T, HÜE B, HILLAIRE-BUYS D et al.: Clonazepam in acute mania: time-blind evolution of clinical response and concentrations in plasma. J. Affect. Disord. (1995) 36:21-27.
12. VIETA E: Novedades en el tratamiento del trastorno bipolar. Panamericana, Madrid (2003).
13. MÜLLER-OERLINGHAUSEN B, RETZOW A, HENN FA et al.: Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group. J. Clin. Pychopharmacol. (2000) 20(2):195-203.
14. BYMASTER FP, RASMUSSEN K, CALLIGARDO DO et al.: In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. J. Clin. Psychiatry (1997) 58(Suppl. 10):28-36.
15. BYMASTER F, PERRY KW, NELSON DL et al.: Olanzapine: a basic science update. Br. J. Psychiatry Suppl. (1999) 37:36-40.
16. WADENBERG ML, SOLIMAN A, VANDERSPECK SC et al.: Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology (2001) 25:633-641.
17. KECK PE, MCELROY SL, STRAKOWSKI SM et al.: Antipsychotics in the treatment of mood disorders and the risk for tardive dyskinesia. J. Clin. Psychiatry (2000) 61(Suppl. 4):33-38.
18. ZAJECKA JM, WEISLER R, SACHS G et al.: A comparison of the efficacy, safety and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J. Clin. Psychiatry (2002) 63(12):1148-1155.
19. VIETA E: Olanzapine versus divalproex in the treatment of mania. J. Clin. Psychiatry (2003) 64:1266.
20. TOHEN M, SANGER T, MCELROY S et al.: Olanzapine versus placebo in the treatment of acute mania. Am. J. Psychiatry (1999) 156:702-709.
21. TOHEN M, JACOBS TG, GRUNDY SL et al.: Efficacy of olanzapine in acute bipolar mania: a double-blind placebo controlled-study. Arch. Gen. Pychiatry (2000) 57:841-849.
22. TOHEN M, BAKER RW, ALTSHULER LL et al.: Olanzapine versus divalproex in the treatment of acute mania. Am. J. Psychiatry (2002) 159:1011-1017.
23. BERK M, ICHIM L, BROOK S: Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. Int. Clin. Pychopharmacol. (1999) 14:339-343.
24. TOHEN M, CHENGAPPA KN, SUPPES T et al.: Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania on patients partially nonresponsive to valproate or lithium monotherapy. Arch. Gen. Psychiatry (2002) 59(1):62-69.
25. TOHEN M, GOLDBERG JF, GONZÁLEZ-PINTO AM et al.: A 12-week,double-blind comparison of olanzapine versus haloperidol in the treatment of mania. Arch. Gen. Pychiatry (2003) 60:1218-1226.
26. BAKER RW: A three-week comparison of olanzapine versus risperidone in the treatment of bipolar mania: improvement in manic and depressive symptoms and treatment adherence. 15th Annual Meeting of the American Psychiatric Association, San Francisco, USA. May 17-22 (2003).
27. MEEHAN K, ZHANG F, DAVID S et al.: A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam or placebo in treating acutely agitated patients diagnosed with bipolar mania. J. Clin. Pychopharmacol. (2001) 21(4):389-397.
28. BALDESSARINI RJ, HENNEN J, WILSON M et al.: Olanzapine versus placebo in acute mania: treatment responses in subgroups. J. Clin. Psychopharmacol. (2003) 23(4):370-376.
29. GONZÁLEZ-PINTO A, LALAGUNA B, MOSQUERA F et al.: Use of olanzapine in dysphoric mania. J. Affect. Disord. (2001) 66:247-253.
30. BENAZZI F, AKISKAL HS: Clinical and factor analytic-validation of depressive mixed states: a report from the Ravenna-San Diego collaboration. Curr. Opin. Psychiatry (2003) 16(Suppl. 2):S71-S78.
31. TOHEN M, VIETA E, CALABRESE JR et al.: Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar depression. Arch. Gen. Psychiatry (2003) 60:1079-1088.
32. VIETA E, REINARES M, CORBELLA B et al.: Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder. J. Clin. Psychopharmacol. (2001) 21:469-473.
33. SANGER TM, GRUNDY SL, GIBSON PJ et al.: Long-term olanzapine therapy in the treatment of bipolar disorder: an open-label continuation phase study. J. Clin. Psychiatry (2001) 62:273-281.
34. TOHEN M, KETTER MA, ZARATE CA et al.: Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am. J. Psychiatry (2003) 160(7):1263-1271.
35. TOHEN M, CHENGAPPA KNR, SUPPES T: Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood-stabiliser v. mood-stabiliser alone. Br. J. Psychiatry (2004) 184:337-345.
36. TOHEN M, MARNEROS A, BOWDEN C et al.: Olanzapine versus lithium in relapse prevention in bipolar disorder: a randomized double-blind controlled 12-month clinical trial. Bipolar Disord. (2002) 5(Suppl.):135.
37. TOHEN M: Olanzapine versus placebo in relapse prevention in bipolar disorder. 156th Annual Meeting of the American Psychiatric Association, San Francisco, USA. May 17-22 (2003).
38. SANGER TM, TOHEN M, VIETA E et al.: Olanzapine in the treatment of acute bipolar disorder with rapid cycling. J. Affect. Disord. (2003) 73:155-161.
39. VIETA E, CARNE X: The use of placebo in clinical trials on bipolar disorders revisited: a new approach for an old debate. Psychother. Pychosom. (In Press).
40. KECK PE, CORYA SA, CALABRESE JR et al.: Acute treatment of rapid cycling bipolar I depression: a double-blind placebo controlled subanalysis of olanzapine/fluoxetine combination. J. Affect. Disord. (In Press).
41. VIETA E, CALABRESE JR, HENNEN J et al.: Comparison of rapid cycling and non-rapid cycling bipolar I manic patients with during treatment with olanzapine. J. Clin. Psychiatry (In Press).
42. MCINTYRE, RS: Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. J. Clin. Psychiatry (2002) 63(Suppl. 3):15-20.
43. AMERICAN DIABETES ASSOCIATION, AMERICAN PSYCHIATRIC ASSOCIATION, AMERICAN ASSOCIATION OF CLINICAL ENDOCRIONOLOGISTS, NORTH AMERICAN ASSOCIATION FOR THE STUDY OF OBESITY: Consensus Development Conference in Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care (2004) 27:596-601.
44. VIETA E, SÁNCHEZ-MORENO J, GOIKOLEA JM et al.: Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder. J. Clin. Psychopharmacol. (In Press).
45. VIETA E: Atypical antipsychotics in the treatment of mood disorders. Curr. Opin. Psychiatry (2003) 16:23-27.